| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -7.7 | -7.3 |
| Net income | -7.7 | -7.3 |
| EPS (diluted, $ a share) | $-0.53 | $-1.35 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CING. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cingulate Inc.: key numbers
- Share price
- $3.75Close, Nov 16
- Market cap
- $56.1M
- Shares outstanding
- 14.96MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cingulate Inc.
All →Cingulate Financial Results
Cingulate reported Q3 2026 financial results, highlighting a cash position of $23.2 million and progress on its CTx-1301 NDA resubmission. The company has substantially completed manufacturing work to address FDA CMC requests and expects to resubmit the NDA between December 2026 and January 2027. Additionally, the company added Maxim Group LLC as a sales agent to its existing $100 million ATM equity offering program.
- Term
- Q3 2026
“With the manufacturing work substantially complete, we are now finalizing the data and documentation needed to resubmit the NDA for CTx-1301, and we expect to do so by January 2027, potentially sooner.”
Shane J. Schaffer, Chairman and CEO
“Importantly, the FDA’s Complete Response Letter did not raise any concerns about the clinical safety or efficacy of CTx-1301. We thank our shareholders for their patience and continued support as we work to bring this treatment to patients with ADHD.”
Shane J. Schaffer, Chairman and CEO
Cingulate Business Update
Cingulate Inc. provided a regulatory update on its lead ADHD asset, CTx-1301, following a previously received FDA Complete Response Letter (CRL). The company has substantially completed the required manufacturing work to address the FDA's requests and expects to resubmit its New Drug Application (NDA) between December 2026 and January 2027.
Cingulate Executive Compensation
Cingulate Inc.'s subsidiary, Cingulate Therapeutics LLC, entered into an amendment to the employment agreement of Matthew N. Brams, the company's Executive Vice President and Chief Medical Officer. The amendment extends the trial period for Mr. Brams' full-time employment from September 30, 2026, to December 31, 2026.
- Term
- through Dec 2026